Sign in
Taking people in United StatesNo phase

Artificial pancreas device study in type 1 diabetes and heart health

Tests an automated insulin pump and glucose monitor in adults with type 1 diabetes.

Key facts

Who runs it
University of Virginia
Where
Charlottesville, United StatesSee the site
Trial code
Registry title
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
Status
Recruiting
People taking part
40 people, planned
Started
9 Sept 2023
Expected to end
30 Mar 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Tandem t:slim X2 with Control-IQ Technology
  • Sensor augmented pump (SAP) therapy
Record updated
25 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 40 with type 1 diabetes for at least one year who use insulin. It studies an artificial pancreas system and heart health.

Age
18 to 40 years
Sex
All sexes can join.
Disease stage
Type 1 diabetes for at least one year, on insulin for at least six months. Hemoglobin A1c below 10.5% (91 mmol/mol), body mass index 18-30 kg/m2, blood pressure below 140/90 mmHg.
Earlier treatment
Must have used insulin for at least six months. Must use only lispro (Humalog) or aspart (Novolog) insulin during the study and not start any new non-insulin glucose-lowering drug. Cannot currently use any non-insulin glucose-lowering drug.
Biomarker or test result
Total daily insulin dose of at least 10 U/day. Hemoglobin not below 11 g/dL for women or 12 g/dL for men.

Main reasons for not taking part

  • Severe low blood sugar with seizure or loss of consciousness, or diabetic ketoacidosis, in the past 12 months
  • Earlier heart disease, or a stroke in the past 12 months
  • Current smokers, or people who quit smoking less than 2 years ago
  • Pregnant or breastfeeding women
  • Nerve damage, large amounts of albumin in the urine, or eye disease beyond mild nonproliferative retinopathy

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Clinical diagnosis, based on World Health Organization criteria, of type 1 diabetes for at least one year
  • Currently using insulin for at least six months
  • Ages 18-≤40 years
  • Hemoglobin A1c <10.5%
  • Body mass index 18-30 kg/m2
  • Blood pressure <140/90 mmHg
  • For females, not currently known to be pregnant or breastfeeding
  • If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative serum or urine pregnancy test will be required for all females of childbearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued
  • Both pump and MDI users will use insulin parameters such as carbohydrate ratio and correction factors consistently in order to dose insulin for meals or corrections; pump users will have history of entering this information into their pump
  • Willingness to suspend use of any personal CGM for the duration of the clinical trial once the study CGM is in use
  • Access to internet and willingness to upload data during the study as needed, including data generated prior to the start of the study
  • Current use of a glucometer that is downloadable; or willingness to use a study glucometer
  • Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol
  • Willingness to use personal lispro (Humalog) or aspart (Novolog) and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study
  • Total daily insulin dose (TDD) at least 10 U/day
  • Willingness not to start any new non-insulin glucose-lowering agent during the trial

Who cannot take part

  • Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment
  • Diagnosis of diabetic ketoacidosis in the 12 months prior to enrollment
  • Prior diagnosis of cardiac disease (e.g., myocardial infarction, congestive heart failure)
  • Cerebrovascular accident in the 12 months prior to enrollment
  • Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
  • History of hypersensitivity or prior adverse reaction (e.g., anaphylaxis or angioedema) to IV regular insulin infusion
  • History of hypersensitivity or prior adverse reaction to Definity microbubble infusion
  • Uncontrolled resting arterial hypertension
  • Conditions that would make use of a CGM difficult (e.g., blindness, severe arthritis, immobility)
  • Hemophilia or any other bleeding disorder
  • Currently being treated for a seizure disorder
  • A medical condition or medication, which in the opinion of the investigator or designee, would put the participant or study at risk
  • Screening Electrocardiogram (ECG) findings indicative of arrhythmia, sinus node disease, or ischemic heart disease
  • Concurrent use of any non-insulin glucose-lowering agent (including metformin, GLP-1 agonists, pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, and/or sulfonylureas)
  • Any woman with hemoglobin (Hgb) <11 g/dL or any man with Hgb <12 g/dL on screening laboratory evaluation (i.e., complete blood count)
  • Diagnosis of peripheral neuropathy (assessed by monofilament examination), macroalbuminuria (urine albumin:creatinine >300 mg per g), or retinopathy beyond mild, nonproliferative retinopathy
  • Unstable (i.e., dose adjustment less than 4 weeks prior to study enrollment) doses of vasoactive medications (e.g., calcium channel blockers, statins, nitrates, alpha-blockers, beta-blockers, ACE inhibitors, etc.)
  • Current smokers or those who have quit smoking <2 years ago
  • Current enrollment in another clinical trial, unless approved by the investigator of both studies or if clinical trial is a non-interventional registry trial

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

Where in United States

  • University of Virginia Health SystemCharlottesville, United StatesContact: Lee M HartlineTaking people

About the trial

What the trial wants to find out

This study will examine the potential cardiovascular effect(s) of artificial pancreas (AP) technology in patients with type 1 diabetes. AP technology is a system of devices that closely mimics the glucose-regulating function of a healthy human pancreas. It includes an insulin pump and a continuous glucose monitor (CGM). In this study, the investigators will research whether improvements in blood glucose levels and blood glucose variability will in turn decrease biomarkers of inflammation and endothelial dysfunction while improving cardiovascular function.

The 2 groups in the trial

  • Closed-loop artificial pancreas (AP)Treatment being tested

    FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM

    Treatment: Tandem t:slim X2 with Control-IQ Technology

  • Sensor Augmented Pump (SAP) therapyTreatment being tested

    Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's current insulin therapy (i.e., either insulin pump or multiple daily injections)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Using Closed-Loop Artificial Pancreas Technology to Reduce Glycemic Variability and Subsequently Improve Cardiovascular Health in Type 1 Diabetes
Plain-language title
Artificial pancreas device study in type 1 diabetes and heart healthGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05653518, who can take part
Record updated
25 February 2026